

Product Information

Product ID F5968

CAS No. 849217-64-7

Chemical Name

Synonym GSK-1363089, GSK1363089

Formula C₃₄H₃₄F₂N₄O₆

Formula Wt. 632.65

Melting Point


Purity ≥98%

Solubility Relatively insoluble in water and ethanol. Soluble in DMSO to 127 mg/mL.

Store Temp -20°C

Ship Temp Ambient

Description Foretinib is an inhibitor of ROS1, MET, Ron, Axl, Tie-2, and VEGFR2 that exhibits anticancer chemotherapeutic and anti-angiogenic activities. In subjects with squamous cell carcinoma, foretinib decreases tumor size. In hepatocellular carcinoma cells, foretinib increases expression of p27 and Bim, decreases expression of cyclin B1 and p-c-Myc, and induces G2/M phase cell cycle arrest, inhibiting cell growth and migration as well as tumor growth and angiogenesis.



Bulk quantities available upon request

Product ID	Size
F5968	5 mg
F5968	10 mg
F5968	25 mg

References Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. *PLoS One*. 2013;8(3):e54014. PMID: 23516391.

Seiwert T, Sarantopoulos J, Kallender H, et al. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. *Invest New Drugs*. 2013 Apr;31(2):417-24. PMID: 22918720.

Huynh H, Ong R, Soo KC. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. *Angiogenesis*. 2012 Mar;15(1):59-70. PMID: 22187171.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.